TY - JOUR
T1 - Dose escalation of second-line sunitinib results in rapid partial remission of multiple hepatic metastases
AU - Guevremont, Catherine
AU - Mija, Florin I.
AU - Isbarn, Hendrik
AU - Jeldres, Claudio
AU - Lughezzani, Giovanni
AU - Sun, Maxine
AU - Audet, Pascale
AU - Perrotte, Paul
AU - Karakiewicz, Pierre I.
PY - 2009/12
Y1 - 2009/12
N2 - A 58-year-old man with metastatic clear cell renal cell carcinoma on sunitinib therapy, who previously failed on sorafenib, was found to have progression of multiple hepatic metastases; he was on a standard sunitinib dose of 50 mg/day (4 weeks on, 2 weeks off). Due to the unavailability of alternative therapies, a sunitinib dose escalation of 50 mg/day was attempted. After one 6-week cycle of continuously dosed sunitinib 50 mg, the hepatic lesions regressed. After the second cycle, virtual disappearance of the lesions was recorded. There was no added toxicity. These findings suggest that sunitinib dose escalation to 50 mg/day using continuous daily administration dosing might represent a valid, effective and well-tolerated therapeutic option in patients who progress on standard sunitinib therapy.
AB - A 58-year-old man with metastatic clear cell renal cell carcinoma on sunitinib therapy, who previously failed on sorafenib, was found to have progression of multiple hepatic metastases; he was on a standard sunitinib dose of 50 mg/day (4 weeks on, 2 weeks off). Due to the unavailability of alternative therapies, a sunitinib dose escalation of 50 mg/day was attempted. After one 6-week cycle of continuously dosed sunitinib 50 mg, the hepatic lesions regressed. After the second cycle, virtual disappearance of the lesions was recorded. There was no added toxicity. These findings suggest that sunitinib dose escalation to 50 mg/day using continuous daily administration dosing might represent a valid, effective and well-tolerated therapeutic option in patients who progress on standard sunitinib therapy.
UR - http://www.scopus.com/inward/record.url?scp=76749105995&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=76749105995&partnerID=8YFLogxK
M3 - Article
C2 - 20019964
AN - SCOPUS:76749105995
VL - 3
JO - Journal of the Canadian Urological Association
JF - Journal of the Canadian Urological Association
SN - 1911-6470
IS - 6
ER -